Optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis

CONCLUSION: The combination of TACE and sorafenib significantly can improve TTP and PFS, and reduce the level of risk of adverse reactions of unresectable HCC, especially in the combination before TACE.PMID:34628285 | DOI:10.1016/j.tranon.2021.101238
Source: Translational Oncology - Category: Cancer & Oncology Authors: Source Type: research